| March 18, 2008 |
| September 3, 2008 |
| January 2008 |
| July 2008 (final data collection date for primary outcome measure) |
| Assess the efficacy of diclofenac in subjects with mild to moderate ankle sprain. [ Time Frame: 7 days ] [ Designated as safety issue: No ] |
| Assess the efficacy of diclofenac in subjects with mild to moderate ankle sprain. [ Time Frame: 7 days ] [ Designated as safety issue: Yes ] |
| Complete list of historical versions of study NCT00640705 on ClinicalTrials.gov Archive Site |
| Assess the safety and tolerability of diclofenac in subjects with mild to moderate ankle sprain. [ Time Frame: 7 days ] [ Designated as safety issue: No ] |
| Assess the safety and tolerability of diclofenac in subjects with mild to moderate ankle sprain. [ Time Frame: 7 days ] [ Designated as safety issue: Yes ] |
| |
| Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain |
| A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Pain Due to Mild to Moderate Ankle Sprain. |
The primary purpose of this study is to assess the effectiveness of once daily application of a diclofenac sodium patch to the skin near or over the painful area. In this study, the location being studied will be either the left or right ankle.
The secondary purpose of this study is to assess the safety and tolerability of a diclofenac patch on the skin. |
Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain. |
| Phase II, Phase III |
| Interventional |
| Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Ankle Sprain |
- Drug: diclofenac sodium
- Drug: Matching placebo patch
|
- Active Comparator: Topical diclofenac sodium patch
- Placebo Comparator: Topical patch identical in appearance to active comparator, except without diclofenac sodium
|
| |
| |
| Terminated |
| 170 |
| October 2008 |
| July 2008 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- 18 to 75 years of age
- Has sustained a painful Grade 1 or 2 ankle sprain (Appendix H) no more than 48 hours prior to study entry
- Presence of pain of at least 5, with a maximum of 9, on an 11-point Numerical Rating Scale (NRS)
Exclusion Criteria:
- Grade 3 ankle sprain or bilateral sprain (see Appendix H)
- Previous injury to the same ankle within 3 months prior to current injury
- Aspirin or short half-life NSAID use within 12 hours, or longer half-life NSAID use within 24 hours prior to study entry (Appendix B)
- Opioid use within 24 hours prior to study entry
- Topical treatment, other than ice packs, applied to the painful region since time of injury
- A history of peptic ulcer disease within 1 year of study entry, any history of gastrointestinal bleeding or coagulation disorder
- A history of, or evidence for, underlying disease in the injured ankle, such as osteoarthritis or gout
- Clinically significant, poorly controlled pulmonary, gastrointestinal, hepatic, renal, endocrine, or cardiovascular disease
- A history of hypersensitivity to diclofenac or diclofenac-containing products
- A history of intolerance to acetaminophen (rescue medication in this trial)
- A history of skin sensitivity to adhesives (e.g. adhesive tape)
- Pregnant or breastfeeding women and women of child-bearing potential not using effective means of contraception
|
| Both |
| 18 Years to 75 Years |
| No |
| Contact information is only displayed when the study is recruiting subjects |
| United States |
| |
| NCT00640705 |
| Dan Levitt, MD, Cerimon Pharmaceuticals, Inc. |
| DCF-002 |
| Cerimon Pharmaceuticals |
| PPD |
| Study Director: |
Dan Levitt, MD |
Cerimon Pharmaceuticals |
|
|
| Cerimon Pharmaceuticals |
| September 2008 |
